Corrections: Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care
Article first published online: 30 NOV 2011
Copyright © 2011 American Association for the Study of Liver Diseases
Volume 54, Issue 6, pages 2280–2281, December 2011
How to Cite
- Issue published online: 30 NOV 2011
- Article first published online: 30 NOV 2011
Vol. 54, Issue 5, 1547–1558, Article first published online: 28 OCT 2011
In the November 2011 issue of Hepatology, in the article entitled “Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care” (volume 54, pages 1547–1548), by Innes et al, lines 22 and 23 in the abstract should list liver-related morbidity instead of LMR. Below is the corrected abstract in its entirety.:
Our objective was to address two shortfalls in the hepatitis C virus (HCV) literature: (1) Few data exist comparing post-treatment liver-related mortality/morbidity in HCV-sustained virologic response (SVR) patients to non-SVR patients and (2) no data exist examining liver-related morbidity among treatment response subgroups, particularly among noncirrhotic SVR patients, a group who in the main are discharged from care without further follow-up. A retrospective cohort of 1,215 previously naïve HCV interferon patients (treated 1996-2007) was derived using HCV clinical databases from nine Scottish clinics. Patients were followed up post-treatment for a mean of 5.3 years. (1) By Cox-regression, liver-related hospital episodes (adjusted hazard ratio [AHR]: 0.22; 95% confidence interval [CI]: 0.15-0.34) and liver-related mortality (AHR: 0.22; 95% CI: 0.09-0.58) were significantly lower in SVR patients, compared to non-SVR patients. (2) Rates of liver-related hospitalization were elevated among all treatment subgroups compared to the general population: Among noncirrhotic SVR patients, adjusted standardized morbidity ratio (SMBR) up to 5.9 (95% CI: 4.5-8.0); among all SVR patients, SMBR up to 10.5 (95% CI: 8.7-12.9); and among non-SVR patients, SMBR up to 53.2 (95% CI: 49.4-57.2). Considerable elevation was also noted among patients who have spontaneously resolved their HCV infection (acontrol group used to gauge the extent to which lifestyle factors, and not chronic HCV, can contribute to liver-related morbidity), SMBR up to 26.8 (95% CI: 25.3-28.3). Conclusions: (1) Patients achieving an SVR were more than four times less likely to be hospitalized, or die for a liver-related reason, than non-SVR patients and (2) although discharged, noncirrhotic SVR patients harbor a disproportionate burden of liver-related morbidity; up to six times that of the general population. Further, alarming levels of liver-related morbidity in spontaneous resolvers is an important finding warranting further study.
The publisher regrets the error.